Breast conserving surgery in BRCA1, BRCA2, CHEK2- mutation associated breast cancer

Abstract

Nowadays, the success of chemotherapy for breast cancer demonstrates high sensitivity and effectiveness, and therefore it has become possible to increasingly use breast conserving surgery treatment. Genetically associated breast cancer patients it is a separate clinical group, the treatment of which should take into account the carriage of mutations in the BRCA1, BRCA2, CHEK2 genes. Until now, the possibility of breast conserving surgery in such patients remains debatable. After all, we often talk in such patients not only about the need to perform a mastectomy, but also about a prophylactic mastectomy from the contralateral side to minimize the risks of cancer. Is it acceptable to perform breast conserving treatment in such patients? This article analyzes the experience of well-known foreign oncologists, as well as analyzes their own experience of the Department of Oncology and Radiology RUDN University, Head of the Department of Oncology and Reconstructive Surgery of the Mammary Gland and Skin, P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation.